From Nasdaq:

A new study led by Balázs Szigeti and with involvement of researchers Brandon Weiss, Fernando E Rosas, David Erritzoe, David Nutt and Robin Carhart-Harris found evidence of suggestibility predicting an antidepressant response for patients receiving psilocybin therapy. The study aimed to understand the link between pre-trial expectancy, suggestibility and response to treatment in a previously conducted clinical trial comparing escitalopram and COMPASS Pathways‘ (NASDAQ:CMPS) synthetic psilocybin, COMP360, in the treatment of 55 patients with Major Depressive Disorder (MDD.) Read more HERE.

The European Union has allocated 6.5 million euros ($7 million) from its Horizon Europe program to finance PsyPal, a multisite clinical study focusing on the use of psychedelic-assisted therapy. This initiative, led by the University Medical Centre Groningen (UMCG) in the Netherlands and in collaboration with HumanKindLabs, represents the EU’s first investment in this area of research. The study aims to evaluate the effectiveness of psilocybin therapy in reducing psychological and existential distress in patients with progressive, incurable diseases needing palliative care, specifically targeting conditions like chronic obstructive pulmonary disorder (COPD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and atypical Parkinson’s disease (APD). Continue reading HERE.

The new treatments, given to two people under the guidance of Dr. Eli Kotler and Dr. Ted Cassidy, are framed within Australia’s Therapeutic Goods Administration (TGA) program authorizing psychiatrists to provide these medicines for specific mental health conditions. Kotler and Cassidy, early graduates of Mind Medicine Australia (MMA) in psychedelic-assisted therapies, also supplied the psychedelics to the patients who were treated in Melbourne. Read more HERE.

Welcome to the inaugural episode of the Benzinga Psychedelics Podcast. In this exciting kickoff, we’re joined by Joel Latham, experienced biotech industry leader and CEO of Incannex Healthcare (NASDAQ:IXHL). Dive into our engaging conversation as we explore Incannex’s strategic expansion into broader markets, its pioneering role in Australia’s psychedelic-assisted therapies and its management of a substantial drug portfolio. Listen here.

GOP-Led Senate Bill In Indiana Targets PTSD, Depression With Psilocybin Research For Veterans, First Responders. Biden-Challenger Marianne Williamson Blasts White House, Congress Over Sluggish Cannabis Reform. Cannabis Crusader Dana Beal’s Incarceration: A Blow To Legalization Advocacy And Psychedelic Policy Reform. FDA Green Lights Cybin’s (NYSE:CYBN) Psychedelic Clinical Study Assessing Generalized Anxiety. Numinus Wellness (OTC:NUMIF) Continues Tight Expense Management With Strategic Reviews Underway. Is Ketamine Efficacious For Depression And Other Mental Health Conditions? The Top 10 Studies Of 2023 Shed Some Light. Can Psychedelics Affect Personality Traits And Vice Versa? Key Insights From Researchers

AdvisorShares Psychedelics ETF (NYSE:PSIL) opened Monday, Jan. 22 at $1.37, following prior weeks’ opening at $1.44, $1.41 and $1.42 (Jan. 16, 8 and 2, respectively.) On Friday, Jan. 26 it closed at $1.43, following prior weeks’ closings at $1.37, $1.47 and $1.44 (Jan. 19, 12 and 5, respectively.)Week’s highest was $1.44 during Friday 26, vs. prior weeks’ highest at $1.45, $1.64 and $1.62.Week’s lowest was opening price $1.37, vs. prior weeks’ lowest at $1.39, $1.41 and $1.35.

COMPASS Pathways closed at $10.64, jumping high from prior weeks’ closings at $ 8.02, $8.44 and $8.76, respectively.  GH Research (NASDAQ:GHRS) closed at $7.25, also significantly jumping from prior weeks’ closings at $5.86, $6.03 and $5.37. Incannex Healthcare (NASDAQ:IXHL) closed at $4.62, an uptake as of prior weeks’ closings at $4.05, $4.30 and $4.10. Mind Medicine (MindMed) (NASDAQ:MNMD) closed at $3.69, keeping the trend as per prior closings ($3.60, $3.96 and $4.13.)  Bright Minds Biosciences (NASDAQ:DRUG) closed at $3.14, higher than prior weeks’ closings at $1.93, $1.93 and $1.68. Atai Life Sciences (NASDAQ:ATAI) closed at $1.72, keeping the trend as per prior weeks’ closings ($1.69, $1.96 and $1.64.)  Silo Pharma (NASDAQ:SILO) closed at $1.54, slight uptake as of prior closings at $1.38, $1.45 and $1.46. Clearmind Medicine (NASDAQ:CMND) closed at $1.46, an uptake from the two immediate prior closings at $1.06 and $1.34, yet still behind three-weeks-past at $2.28 Seelos Therapeutics (NASDAQ:SEEL) closed at $1.07, down from prior weeks’ closings at $1.28, $1.44 and $1.34. Enveric Biosciences (NASDAQ:ENVB) closed at $0.90, falling from prior closings at $1.09, $1.27 and $1.27.



Read more: Psyched: Suggestibility And Psychedelics’ Effects, EU’s $7M Research Fund, Australia’s Treatment Delivery, BZ Podcast And More